What zerlasiran is
Zerlasiran is a small interfering RNA (siRNA) developed by Silence Therapeutics. Like olpasiran and lepodisiran, it silences the messenger RNA of the LPA gene in the liver, reducing production of apolipoprotein(a) and therefore of lipoprotein(a), or Lp(a). It is given by injection under the skin at intervals of several months.
Clinical evidence
Phase 1
A single- and multiple-dose study, published in JAMA in 2024, found no serious adverse events. In the multiple-dose group, with a median baseline Lp(a) of 288 nmol/L, two doses produced maximal median Lp(a) changes of −242 to −310 nmol/L across dose groups, compared with +19 nmol/L with placebo.
Phase 2
The Phase 2 trial enrolled 178 patients with a median baseline Lp(a) of 213 nmol/L. Published in JAMA in December 2024:
| Regimen | Time-averaged placebo-adjusted change, baseline to week 36 | Median change at week 36 |
|---|---|---|
| 450 mg every 24 weeks | −85.6% | −94.5% |
| 300 mg every 16 weeks | −82.8% | −96.4% |
| 300 mg every 24 weeks | −81.3% | −90.0% |
Source: Nissen et al., JAMA (2024).
The most common treatment-related adverse effects were injection-site reactions, mostly mild pain in 2.3% to 7.1% of participants on the day after dosing. There were 20 serious adverse events in 17 patients, none considered related to the study drug.
Development status
Zerlasiran's story since Phase 2 has been corporate rather than clinical:
- Phase 3 readiness. Silence reports that its research costs fell in 2026 mainly because "zerlasiran Phase 3 readiness" was completed in 2025 (company-reported, November 2026 filing). No Phase 3 trial is listed on ClinicalTrials.gov.
- Acquisition. On October 19, 2026, Silence announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, through a U.K. scheme of arrangement. The transaction is expected to close in the first quarter of 2027 (company-reported).
The sources we reviewed do not say what Merck KGaA plans for zerlasiran after the deal closes.
Scientific perspective
Zerlasiran's Phase 2 Lp(a) reductions are in the same range as other siRNAs and deeper than those achieved by pelacarsen in its failed outcomes trial. But no siRNA has yet shown that lowering Lp(a) reduces cardiovascular events. A Phase 3 outcomes trial would need to enroll thousands of patients and run for years, the same expensive, long-horizon test that pelacarsen did not pass.
Development perspective
- Regulatory status: zerlasiran has no FDA approval.
- Stage: Phase 2 complete, with no registered Phase 3. Programs moving from Phase 2 to Phase 3 have historically advanced only about 29% of the time, and about 15% have reached approval. Here the gating decision may be strategic rather than scientific. See What Are the Chances of FDA Approval After Phase 2?
- What to watch: the acquirer's first public statements about the program after closing, and whether a Phase 3 trial is registered.
Competitive context
Zerlasiran would enter Phase 3 well behind Amgen's olpasiran and Lilly's lepodisiran, whose outcomes trials are already fully enrolled or running. Its value to a new owner may depend on whether those earlier trials succeed, and on whether zerlasiran's dosing or profile offers an advantage.
Development timeline
- Dec 13, 2022Phase 2 trial in patients with elevated Lp(a) at high risk of cardiovascular events begins. Registry
- May 14, 2024Phase 1 single- and multiple-dose results published in JAMA. Peer-reviewed
- Dec 17, 2024Phase 2 results published: time-averaged Lp(a) reductions of 81% to 86% versus placebo through week 36. Peer-reviewed
- Sep 4, 2026Read-across: pelacarsen, another Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported
- Oct 19, 2026Silence Therapeutics announces an agreement to be acquired by Merck KGaA, Darmstadt, Germany; closing expected in Q1 2027. Company-reported
What could change the outlook
- Completion of Merck KGaA's acquisition of Silence, expected in Q1 2027 (company-reported), and any statement about zerlasiran's development plans.
- Registration of a Phase 3 cardiovascular outcomes trial on ClinicalTrials.gov.
- Results of other Lp(a) outcomes trials (olpasiran, lepodisiran), which will determine how attractive the class is for further investment.
- Any change in Silence's description of the program in its remaining SEC filings before the deal closes.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Zerlasiran. Company-reported, not independently verified.
- Quarterly reportCompany-reportedNov 12, 2026
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
The $11.2 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs. • G&A Expenses: General and administrative (G&A) expenses were $4.9 million for the three months ended September 30, 2026, compared to $5.8 million for the three months ended...
- Quarterly reportCompany-reportedAug 10, 2026
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
The $8.4 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs. • G&A Expenses: General and administrative (G&A) expenses were $4.7 million for the three months ended June 30, 2026, compared to $5.1 million for the three months ended June 30...
- Investor presentationCompany-reportedJun 23, 2026
June 2026 Corporate Presentation EXHIBIT 99.1
Silencing diseases through precision engineered medicines created with proprietarysiRNA technology We are Silencing Genes to Treat Disease Natural: RNAi is a natural biological process that regulates gene expression Precise: each siRNA is intentionally designed to bind only to the target gene transcript Durable...